Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
Top Cited Papers
- 1 December 2005
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 366 (9501) , 1945-1953
- https://doi.org/10.1016/s0140-6736(05)67785-9
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- Clinical implications of the JAK2 V617F mutation in essential thrombocythemiaLeukemia, 2005
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disordersBlood, 2003
- Chronic Myeloproliferative DisordersHematology-American Society Hematology Education Program, 2003
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002
- Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and managementBlood Reviews, 2001